Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-24
2005-05-24
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S226200, C514S229800, C536S029100, C544S038000, C544S073000, C544S102000
Reexamination Certificate
active
06897199
ABSTRACT:
The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
REFERENCES:
patent: 6054453 (2000-04-01), Lohray et al.
patent: 6440961 (2002-08-01), Lohray et al.
patent: WO 9919313 (1999-04-01), None
patent: WO 0050414 (2000-08-01), None
patent: 0140159 (2001-06-01), None
patent: 0140165 (2001-06-01), None
patent: 0140166 (2001-06-01), None
patent: 0140169 (2001-06-01), None
patent: 0140170 (2001-06-01), None
patent: 0140171 (2001-06-01), None
patent: 0140172 (2001-06-01), None
patent: 0153257 (2001-07-01), None
Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Chemistry, vol. 31”, 1996, Academic Press, San Diego, p 241-246.*
Nuss, J.M. et al, in “Ann. Reports Med. Chem. vol. 35”, 2000, Academic Press, San Diego, p 211-220.*
Cobb, J. et al, in“Ann. Reports Med. Chem. vol. 33”, 1998, Academic Press, San Diego, p 213-222.*
Willson, T.M. et al, J. Med. Chem., 43 (4), 527-550, 2000.*
Par Stattin, Rudolf Kaaks. Journal of the National Cancer Institute. Oxford: Jul. 16, 2003. vol. 95, Iss. 14; p. 1086.*
Sapone, A. et al, Pharmacogenetics. Jun. 2000;10(4):321-33, Medline 10862523.*
Ishibashi, M. et al., “Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone” Hypertension 40(5)(2002) 687-93Abstract.
Dandona, P. “Endōthelium, inflammation, and diabetes” Curr Diab Rep 2(4) pp 311-5 (2002).
Breyer, Guan Y. “Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease” Kidney Int. 60(1) (2001) pp 14-30Abstract.
Dubuquoy, L., et al. “Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease” Gastroenterol Clin Biol 24(8-9) (2000) pp 719-24Abstract.
Messier, Claude, et al. “Glucose regulation and cognitive functions:relation to Alzheimer's disease and diabetes” Behavioural Brain Research 75 (1996) pp 1-11.
Hull, M., et al. “Pathways of inflammatory activation in Alzheimer's disease:potential targets for disease modifying drugs” Curr Med Chem 9(1) (2002) pp 83-8Abstract.
Watson GS, et al. “The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment” CNS Drugs 17(1) (2003) pp 27-45Abstract.
Kopelovich, L., et al. “Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents” Mol Cancer Ther 1(5) (2002) pp 357-63Abstract.
Pershadsingh, H.A. “Pharmacological peroxisome proliferator-activated receptory ligands:emerging clinical indications beyond diabetes” Expert Opin. Invest. Drugs 8(11) (1999) pp 1859-1872Abstract.
The Diabetes-Dementia Connection, Clinician Reviews, Mar. 2000.
J. Kuusisto, et al.,British Medical Journal, Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. No. 7115, vol. 315, Oct. 25, 1997.
Gabe Mirkin, M.D.,Diabetes and Colon Cancer/Insulin Resistance, Report #6502, May 14, 1995, CBS Radio News.
B. Isaksson, et al.,Pancreatology, Basic: Pancreatic Cancer, 2:217-361, 2002.
Hsing AW, et al., J National Cancer Institute,Insulin resistance and prostate cancer risk, 95(1):67-71, Jan. 1, 2003.
Lois Baker,University at Buffalo Reporter, Study links cancer risk to insulin resistance, vol. 32, No. 16, Jan. 18, 2001.
Festa A, et al. Circulation,chronic subclinical inflammation as part of the insulin resistance, 102(1):42-7, Jul. 4, 2000.
Chebiyyam Prabhakar
Gaddam Om Reddy
Gutta Madhusudan
Mamillapalli Ramabhadra Sarma
Dr. Reddy's Laboratories Ltd.
Ladas & Parry LLP
McKenzie Thomas C.
Wilson James O.
LandOfFree
Pharmaceutically acceptable salts of phenoxazine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically acceptable salts of phenoxazine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically acceptable salts of phenoxazine and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3415162